When will Kiniksa Pharmaceuticals report its third quarter 2024 financial results?

Kiniksa Pharmaceuticals will host its third quarter 2024 financial results conference call on October 29, 2024, at 8:30 a.m. Eastern Time.

How can investors access the conference call and live webcast?

The conference call will be accessible via a live webcast on Kiniksa's investor relations website.

What will telephone participants receive after registering for the call?

All telephone participants will receive a confirmation email with details including the dial-in number, unique passcode, and registrant ID to access the call.

Will there be a replay available for the conference call, and when?

A replay of the conference call will be available on Kiniksa's website approximately 48 hours after the event.

What is the primary focus of Kiniksa Pharmaceuticals as a biopharmaceutical company?

Kiniksa Pharmaceuticals focuses on discovering and commercializing therapeutic medicines for patients with debilitating diseases, particularly in underserved cardiovascular and autoimmune conditions.

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

10/22/24 4:01:00 PM ET

$KNSA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KNSA alert in real time by email

LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024 at 8:30 a.m. Eastern Time to report its third quarter 2024 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa's website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor Contact

Jonathan Kirshenbaum

(781) 829-3949

[email protected]

Kiniksa Media Contact

Tyler Gagnon

(781) 431-9100

[email protected]

Get the next $KNSA alert in real time by email

Date	Price Target	Rating	Analyst
3/13/2025	$40.00	Buy	Citigroup
9/13/2024	$40.00	Buy	Jefferies
5/3/2024	$34.00	Overweight	Wells Fargo
12/29/2021	$37.00 → $34.00	Buy	B of A Securities

Date

Price Target

Rating

Analyst

3/13/2025

$40.00

Buy

Citigroup

9/13/2024

$40.00

Buy

Jefferies

5/3/2024

$34.00

Overweight

Wells Fargo

12/29/2021

$37.00 → $34.00

Buy

B of A Securities

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Chat with this insight

Q&A

When will Kiniksa Pharmaceuticals report its third quarter 2024 financial results?

How can investors access the conference call and live webcast?

What will telephone participants receive after registering for the call?

Will there be a replay available for the conference call, and when?

What is the primary focus of Kiniksa Pharmaceuticals as a biopharmaceutical company?

Recent Analyst Ratings for
$KNSA

$KNSA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

$KNSA
SEC Filings

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

$KNSA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $489,244 worth of Class A Ordinary Share (17,300 units at $28.28), decreasing direct ownership by 15% to 61,563 units (SEC Form 4)

Director Quart Barry D exercised 27,448 units of Class A Ordinary Share at a strike of $3.80 and sold $833,001 worth of Class A Ordinary Share (27,448 units at $30.35) (SEC Form 4)

CHIEF OPERATING OFFICER Tessari Eben exercised 70,867 units of Class A Ordinary Share at a strike of $10.36 and sold $2,160,035 worth of Class A Ordinary Share (70,867 units at $30.48) (SEC Form 4)

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Chat with this insight

Q&A

When will Kiniksa Pharmaceuticals report its third quarter 2024 financial results?

How can investors access the conference call and live webcast?

What will telephone participants receive after registering for the call?

Will there be a replay available for the conference call, and when?

What is the primary focus of Kiniksa Pharmaceuticals as a biopharmaceutical company?

Recent Analyst Ratings for $KNSA

$KNSA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

$KNSA SEC Filings

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

$KNSA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $489,244 worth of Class A Ordinary Share (17,300 units at $28.28), decreasing direct ownership by 15% to 61,563 units (SEC Form 4)

Director Quart Barry D exercised 27,448 units of Class A Ordinary Share at a strike of $3.80 and sold $833,001 worth of Class A Ordinary Share (27,448 units at $30.35) (SEC Form 4)

CHIEF OPERATING OFFICER Tessari Eben exercised 70,867 units of Class A Ordinary Share at a strike of $10.36 and sold $2,160,035 worth of Class A Ordinary Share (70,867 units at $30.48) (SEC Form 4)

Recent Analyst Ratings for
$KNSA

$KNSA
Analyst Ratings

$KNSA
SEC Filings

$KNSA
Insider Trading